Check for updates

OPEN ACCESS

EDITED BY Yogesh Bhaskar Narkhede, University of Notre Dame, United States

REVIEWED BY Mark R. Estacion, Yale University, United States

*CORRESPONDENCE Donghang Zhang, I zhangdhscu@163.com Yiyong Wei, I 295502476@gg.com

RECEIVED 04 December 2023 ACCEPTED 29 December 2023 PUBLISHED 11 January 2024

CITATION

Zhang D and Wei Y (2024), Role of sodium leak channel (NALCN) in sensation and pain: an overview. *Front. Pharmacol.* 14:1349438. doi: 10.3389/fphar.2023.1349438

COPYRIGHT

© 2024 Zhang and Wei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Role of sodium leak channel (NALCN) in sensation and pain: an overview

Donghang Zhang¹* and Yiyong Wei²*

¹Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China, ²Department of Anesthesiology, Longgang District Maternity and Child Healthcare Hospital of Shenzhen City (Longgang Maternity and Child Institute of Shantou University Medical College), Shenzhen, China

The sodium leak channel (NALCN) is widely expressed in the central nervous system and plays a pivotal role in regulating the resting membrane potential (RMP) by mediating the Na⁺ leak current. NALCN was first reported in 1999, and since then, increasing evidence has provided insights into the structure and functions of NALCN. As an essential component of neuronal background currents, NALCN has been shown to be involved in many important physiological functions, particularly in the respiratory rhythm, as NALCN mutant mice have a severely disrupted respiratory rhythm and die within 24 h of birth. Many patients with NALCN mutations also develop serious clinical syndromes, such as severe hypotonia, speech impairment, and cognitive delay. Recently, emerging studies have clarified the human NALCN structure and revealed additional properties and functions of NALCN. For instance, accumulating evidence highlights that the NALCN is involved in normal sensation and pain. Here, we review the current literature and summarize the role of the NALCN in sensation and pain.


KEYWORDS

NALCN, DRG, spinal cord, pain, sensation

Introduction

Despite the predominant role of potassium leak conductance in maintaining the resting membrane potential (RMP) of neurons, the RMP of most mammalian neurons is considerably depolarized to the potassium equilibrium potential, suggesting that other conductance coexists (Ren, 2011; Lu and Feng, 2012). The sodium leak channel (NALCN) is widely expressed in neurons of the central nervous system (CNS) and has been confirmed to contribute to the RMP in neurons and control its excitability (Lu et al., 2007; Lutas et al., 2016; Shi et al., 2016; Cobb-Lewis et al., 2023). Growing evidence indicates that NALCN is essential for maintaining many biological functions, such as rhythmic behaviors and locomotor behaviors, in both mammals and invertebrates (Lu et al., 2007; Xie et al., 2013; Gao et al., 2015; Yeh et al., 2017; Zhou et al., 2022). Moreover, an increasing number of patients with NALCN mutations have been reported to have severe manifestations similar to those in animals (Lozic et al., 2016; Angius et al., 2018; Bourque et al., 2018; Campbell et al., 2018; Karimi et al., 2020). Therefore, NALCN is essential for maintaining vital functions in organisms.

NALCN was first detected in the rat brain in 1999 (Lee et al., 1999). Since then, NALCN has been found widely expressed in almost all neurons of the CNS in both mammals and invertebrates (Lu et al., 2007; Yeh et al., 2008; Ren, 2011; Lu and Feng, 2012). In the mouse brain, NALCN is also present in oligodendrocytes and at a very low level in astrocytes



Schematic plot of the association between the NALCN and sensation. NALCN: sodium leak channel; DRG: dorsal root ganglion; DSFs: depolarizing spontaneous fluctuations of membrane potential; PBN: parabrachial nucleus; AITC: allyl isothiocyanate. + means increased NALCN expression; means study regions.

(Cahoy et al., 2008). The expression pattern suggested that NALCN plays fundamental roles. Recent studies have shown that NALCN is also abundant in the spinal cord and dorsal root ganglion (DRG) of rodents (Zhang et al., 2021; Li et al., 2021), indicating that NALCN might be implicated in important animal behaviors, such as pain and sensation. Increasing *in vitro* and/or *in vivo* evidence has shown that NALCN is associated with physiological sensation or pain (Figure 1) (Ford et al., 2018; Eigenbrod et al., 2019; Saro et al., 2020; Zhang et al., 2021; Li et al., 2021; Tian et al., 2023; Wu et al., 2023). Here, we will review the current literature to summarize the contribution of the NALCN to sensation and pain.

In vitro evidence

Ford et al. first showed that NALCN controls the intrinsic excitability of spinal-parabrachial nucleus (PBN) projection neurons in developing mice (Ford et al., 2018). Pharmacological inhibition or knockout of NALCN suppresses the intrinsic excitability of spinal-PBN neurons. Furthermore, the authors demonstrated that substance P (SP) can activate NALCN and enhance excitability in spinal-PBN neurons via Src kinase signaling, which is consistent with findings in the brain from previous studies (Lu et al., 2009; Ren, 2011). Their findings suggest that NALCN conductance in spinal-PBN projection neurons may govern ascending nociceptive transmission to the brain and thereby modulate pain perception. However, this study did not validate the role of NALCN in pain sensation or transduction using *in vivo* experiments. In addition, whether NALCN regulates the intrinsic excitability of spinal neurons in adults is unclear.

Depolarizing spontaneous fluctuations of membrane potential (DSFs) are suggested to control the spontaneous discharge of nociceptors, which is associated with prior pain. Tian et al. showed that NALCN partially contributed to regulating the amplitude and frequency of DSFs in nociceptors using nonspecific inhibitors of NALCN, namely, Gd^{3+} and L-703606 (Tian et al., 2023). Highly selective inhibitors or specific knockdown or knockout of NALCN are needed to determine the role of NALCN in DSFs. In addition to NALCN, their findings also highlight an important contribution from diverse ion channels permeable to Na⁺ and/or Ca²⁺, such as Nav1.7, Nav1.8, Nav1.9, TRPV1, TRPA1, TRPM4, and N-type Ca²⁺ channels, some of which have been confirmed to be associated with pain

conditions. Characterization of the relative contributions of these ion channels to the generation of DSFs under pathological conditions may guide the development of more effective molecular targets for the control of pain.

In vivo evidence

Eigenbrod et al. first provided direct evidence that NALCN is associated with pain sensation in vivo (Eigenbrod et al., 2019). These authors aimed to identify the evolutive mechanism of pain insensitivity in multiple African rodents. They found that NALCN was significantly upregulated in the dorsal root ganglia and spinal cord of highveld mole-rats, which was suggested to cause insensitivity to allyl isothiocyanate (AITC)-pain. In in vitro experiments, overexpression of NALCN channels in cultured cells increased background sodium currents, which led to a decrease in cellular input resistance and depolarized RMP, thereby preventing action potential firing by inactivating voltage-gated sodium channels. Thus, extremely increased expression of NALCN at nociceptor terminals could dampen excitation after TRPA1 activation in highveld molerats. Notably, verapamil, a potent blocker of NALCN, could reveal behavioral sensitivity to AITC in highveld mole-rats. However, as verapamil is also a calcium channel antagonist, the exact contribution of NALCN should be determined using completely specific NALCN blockers or by knocking down or knocking out NALCN in the DRG and spinal cord of highveld mole-rats.

Zhang et al. reported that NALCN is also associated with the development of pathological pain in rodents (Zhang et al., 2021). Like in the brain, NALCN was abundantly expressed in the peripheral DRG and spinal cord neurons of rats and mice. In a chronic constriction injury (CCI) model, NALCN expression and function in the DRG and dorsal spinal cord were elevated, which contributed to neuronal sensitization and neuropathic pain, as well as complete Freund's adjuvant (CFA)-induced inflammatory pain (Li et al., 2021). Interestingly, these findings appear to be contrary to those from the study of Eigenbrod et al. (2019), which may be explained by the differentially elevated levels of NALCN expression. The expression level of NALCN determines the extent of RMP depolarization, thereby leading to pain insensitivity or sensitivity. Significant depolarization of the RMP by extreme overexpression of NALCN can inactivate voltage-gated sodium channels and dampen neuronal excitability in highveld mole-rats (Eigenbrod et al., 2019), while the RMP is depolarized by less than 10 mV, which leads to neuronal sensitization in CCI-induced hyperalgesia (Zhang et al., 2021). Nevertheless, all this evidence points to NALCN as an underlying molecular target for pain sensation.

In addition to the DRG and spinal cord, the NALCN in the brain was also found to be related to the regulation of pain. Wu et al. showed that knocking down NALCN in lateral parabrachial nucleus (PBL) glutamatergic neurons alleviated CFA-induced pain in mice (Wu et al., 2023). Their findings further suggested that the NALCN in PBL glutamatergic neurons regulates inflammatory pain via PBLcentral nucleus amygdala (CeA) projections. However, the authors did not use patch recordings or calcium imaging to detect the excitability of PBL glutamatergic neurons when NALCN expression was knocked down, except for simply examining the change in c-fos expression. Moreover, researchers have not confirmed whether NALCN knockdown in PBL induces other abnormal phenotypes.

Saro et al. used *in vivo* experiments to show that NALCN was involved in sensory and thermal signal processing in *C. elegans* (Saro et al., 2020). In their study, two mutated genes, nca-1 and nca-2, were used to examine the role of NALCN in primary nociceptors in *C. elegans*. They showed that both mutations reduced the magnitude of heat-evoked calcium changes and affected thermal sensitivity, while nca-2 mutations also influenced sensory gain and signal kinetics during termination of thermal stimuli. Given the high conservation of NALCN expression and functions across animals, this study may provide new insights into the molecular machinery of ascending nociceptive pathways in sensory perception and important behaviors.

Strengths and weaknesses of the current evidence regarding the role of NALCN in pain and sensation

Current evidence from both in vivo and in vitro experiments indicates that NALCN plays a pivotal role in controlling pain (Eigenbrod et al., 2019; Zhang et al., 2021; Li et al., 2021; Wu et al., 2023). A previous study also indicated that the NALCN determines the intrinsic excitability of spinal projection neurons using in vitro experiments (Ford et al., 2018), which suggests that the NALCN contributes to sensory conduction and pain perception. However, behavioral tests using NALCN knockdown or knockout techniques are still needed to confirm the role of NALCN in controlling sensory conduction from peripheral sites to the central nervous system. Moreover, the role of NALCN in specific neuronal subtypes of the spinal cord needs to be clarified because of the component heterogeneity in both human (Yadav et al., 2023; Zhang et al., 2023) and mouse spinal neurons (Sathyamurthy et al., 2018; Russ et al., 2021). Additionally, the upstream and downstream molecular targets that mediate the effects of NALCN on pain and sensation have not been identified. Notably, two important subunits of NALCN, namely, UNC80 and UNC79, are essential for normal NALCN function (Ren, 2011; Lu and Feng, 2012). Therefore, it will be interesting to determine the role of UNC80 and UNC79 in pain and sensation, which might also be novel targets for controlling pain. More importantly, although NALCN is also widely expressed in the human DRG and spinal cord (Zhang et al., 2021; Zhang et al., 2022), evidence that NALCN regulates pain in humans has not yet been found. Future studies are needed to explore whether NALCN is a key target for controlling human pain, which will spur drug development and facilitate successful clinical translation from rodent findings.

According to the results of recent studies, the role of the NALCN in pain and sensation in peripheral DRG and spinal cord neurons (Ford et al., 2018; Eigenbrod et al., 2019; Zhang et al., 2021; Li et al., 2021; Tian et al., 2023) appears to be more important than that in brain neurons (Wu et al., 2023). However, NALCN may be associated with central sensitization induced by chronic pain because NALCN is widely expressed in the central nervous system and controls neuronal excitability (Lu et al., 2007; Ren, 2011). Future studies may uncover the contribution of the NALCN in central neurons, especially neuronal subtypes, as well as the involved neural circuits in the regulation of pain perception. For example, one study revealed that the NALCN controls the neuronal excitability of spinal-PBN projection neurons (Ford et al., 2018). Therefore, determining the role of NALCN in the spinal-PBN pathway in pain and physiological sensory signaling will be interesting. However, whether NALCN is an underlying molecular target in pain-related brain nuclei, such as the ventral tegmental area (VTA) (Markovic et al., 2021), the central nucleus of the amygdala (CeA) (Zhou et al., 2019; Lin et al., 2022), and the basal forebrain (Zhou et al., 2023), that regulate pain also remains elusive.

Perspectives

Although increasing evidence suggests that NALCN may be a promising molecular target for treating pain conditions, one important obstacle is that highly specific blockers for NALCN are unavailable. N-Benzhydryl quinuclidine compounds have been suggested to be promising inhibitors of NALCN with a certain level of selectivity in in vitro experiments (Hahn et al., 2020), but their role in pain has not yet been explored. Recently, the structural architecture of the human NALCN has been elucidated (Kschonsak et al., 2020; Xie et al., 2020; Zhou et al., 2022; Kschonsak et al., 2022), which will substantially facilitate the discovery of highly selective drugs to potentially treat NALCNrelated disorders, such as pain, by blocking NALCN. Notably, global inhibition of NALCN may cause abnormal functional outcomes, such as respiratory depression; therefore, the discovery of inhibitors targeting the peripheral nervous system, such as the DRG, may be more effective and safer. Therefore, this novel drug should have high selectivity for both NALCN and the peripheral nervous system, which might also be progressed to a clinical therapy. Considering the convenience of the drug delivery route, oral or intravenous administration of NALCN inhibitors is preferred over direct DRG or intrathecal injection, especially when repeated or multiple injections are needed. Notably, whether reduced NALCN activity in the DRG and/or spinal cord leads to abnormal biological functions, such as motor behaviors, needs to be validated in future studies. A recent study revealed that NALCN is also expressed in the glial cells of the DRG and spinal

References

Angius, A., Cossu, S., Uva, P., Oppo, M., Onano, S., Persico, I., et al. (2018). Novel NALCN biallelic truncating mutations in siblings with IHPRF1 syndrome. *Clin. Genet.* 93, 1245–1247. doi:10.1111/cge.13162

Bourque, D. K., Dyment, D. A., MacLusky, I., Kernohan, K. D., and McMillan, H. J. (2018). Periodic breathing in patients with NALCN mutations. *J. Hum. Genet.* 63, 1093–1096. doi:10.1038/s10038-018-0484-1

Cahoy, J. D., Emery, B., Kaushal, A., Foo, L. C., Zamanian, J. L., Christopherson, K. S., et al. (2008). A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. *J. Neurosci.* 28, 264–278. doi:10.1523/JNEUROSCI.4178-07.2008

Campbell, J., FitzPatrick, D. R., Azam, T., Gibson, N. A., Somerville, L., Joss, S. K., et al. (2018). NALCN dysfunction as a cause of disordered respiratory rhythm with central apnea. *Pediatrics* 141, S485–s490. doi:10.1542/peds.2017-0026

Cobb-Lewis, D. E., Sansalone, L., and Khaliq, Z. M. (2023). Contributions of the sodium leak channel NALCN to pacemaking of medial ventral tegmental area and substantia nigra dopaminergic neurons. *J. Neurosci.* 43, 6841–6853. doi:10.1523/JNEUROSCI.0930-22.2023

cord in both humans and rodents (Zhang et al., 2022). The role of NALCN in glial cells should also be determined, as the activities of glial cells are involved in pain sensation. However, no clinical patients with NALCN mutations were reported to have sensory or pain disorders; therefore, it will be interesting to test the sensory functions of patients with NALCN mutations.

Author contributions

DZ: Conceptualization, Supervision, Validation, Writing-original draft, Writing-review and editing. YW: Conceptualization, Supervision, Writing-review and editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. National Natural Science Foundation of China (grant 82301403, DZ). Natural Science Foundation of Sichuan Province (grant 2022NSFSC1399, DZ). Health Commission of Sichuan Province Program (grant 21PJ014, DZ).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Eigenbrod, O., Debus, K. Y., Reznick, J., Bennett, N. C., Sánchez-Carranza, O., Omerbašić, D., et al. (2019). Rapid molecular evolution of pain insensitivity in multiple African rodents. *Science* 364, 852–859. doi:10.1126/ science.aau0236

Ford, N. C., Ren, D., and Baccei, M. L. (2018). NALCN channels enhance the intrinsic excitability of spinal projection neurons. *Pain* 159, 1719–1730. doi:10.1097/j.pain. 000000000001258

Gao, S., Xie, L., Kawano, T., Po, M. D., Guan, S., Zhen, M., et al. (2015). The NCA sodium leak channel is required for persistent motor circuit activity that sustains locomotion. *Nat. Commun.* 6, 6323. doi:10.1038/ncomms7323

Hahn, S., Kim, S. W., Um, K. B., Kim, H. J., and Park, M. K. (2020). N-benzhydryl quinuclidine compounds are a potent and Src kinase-independent inhibitor of NALCN channels. *Br. J. Pharmacol.* 177, 3795–3810. doi:10.1111/bph.15104

Karimi, A. H., Karimi, M. R., Farnia, P., Parvini, F., and Foroutan, M. (2020). A homozygous truncating mutation in NALCN causing IHPRF1: detailed clinical manifestations and a review of literature. *Appl. Clin. Genet.* 13, 151–157. doi:10. 2147/TACG.S261781

Kschonsak, M., Chua, H. C., Noland, C. L., Weidling, C., Clairfeuille, T., Bahlke, O. Ø., et al. (2020). Structure of the human sodium leak channel NALCN. *Nature* 587, 313–318. doi:10.1038/s41586-020-2570-8

Kschonsak, M., Chua, H. C., Weidling, C., Chakouri, N., Noland, C. L., Schott, K., et al. (2022). Structural architecture of the human NALCN channelosome. *Nature* 603, 180–186. doi:10.1038/s41586-021-04313-5

Lee, J. H., Cribbs, L. L., and Perez-Reyes, E. (1999). Cloning of a novel four repeat protein related to voltage-gated sodium and calcium channels. *FEBS Lett.* 445, 231–236. doi:10.1016/s0014-5793(99)00082-4

Li, J., Chen, Y., Liu, J., Zhang, D., Liang, P., Lu, P., et al. (2021). Elevated expression and activity of sodium leak channel contributes to neuronal sensitization of inflammatory pain in rats. *Front. Mol. Neurosci.* 14, 723395. doi:10.3389/fnmol.2021.723395

Lin, Y. L., Yang, Z. S., Wong, W. Y., Lin, S. C., Wang, S. J., Chen, S. P., et al. (2022). Cellular mechanisms underlying central sensitization in a mouse model of chronic muscle pain. *Elife* 11. doi:10.7554/elife.78610

Lozic, B., Johansson, S., Lovric Kojundzic, S., Markic, J., Knappskog, P. M., Hahn, A. F., et al. (2016). Novel NALCN variant: altered respiratory and circadian rhythm, anesthetic sensitivity. *Ann. Clin. Transl. Neurol.* 3, 876–883. doi:10. 1002/acn3.362

Lu, B., Su, Y., Das, S., Liu, J., Xia, J., and Ren, D. (2007). The neuronal channel NALCN contributes resting sodium permeability and is required for normal respiratory rhythm. *Cell* 129, 371–383. doi:10.1016/j.cell.2007.02.041

Lu, B., Su, Y., Das, S., Wang, H., Wang, Y., Liu, J., et al. (2009). Peptide neurotransmitters activate a cation channel complex of NALCN and UNC-80. *Nature* 457, 741–744. doi:10.1038/nature07579

Lu, T. Z., and Feng, Z. P. (2012). NALCN: a regulator of pacemaker activity. *Mol. Neurobiol.* 45, 415–423. doi:10.1007/s12035-012-8260-2

Lutas, A., Lahmann, C., Soumillon, M., and Yellen, G. (2016). The leak channel NALCN controls tonic firing and glycolytic sensitivity of substantia nigra pars reticulata neurons. *Elife* 5, e15271. doi:10.7554/eLife.15271

Markovic, T., Pedersen, C. E., Massaly, N., Vachez, Y. M., Ruyle, B., Murphy, C. A., et al. (2021). Pain induces adaptations in ventral tegmental area dopamine neurons to drive anhedonia-like behavior. *Nat. Neurosci.* 24, 1601–1613. doi:10.1038/s41593-021-00924-3

Ren, D. (2011). Sodium leak channels in neuronal excitability and rhythmic behaviors. *Neuron* 72, 899–911. doi:10.1016/j.neuron.2011.12.007

Russ, D. E., Cross, R. B. P., Li, L., Koch, S. C., Matson, K. J. E., Yadav, A., et al. (2021). A harmonized atlas of mouse spinal cord cell types and their spatial organization. *Nat. Commun.* 12, 5722. doi:10.1038/s41467-021-25125-1

Saro, G., Lia, A. S., Thapliyal, S., Marques, F., Busch, K. E., and Glauser, D. A. (2020). Specific ion channels control sensory gain, sensitivity, and kinetics in a tonic thermonociceptor. *Cell Rep.* 30, 397–408. e394. doi:10.1016/j.celrep.2019.12.029

Sathyamurthy, A., Johnson, K. R., Matson, K. J. E., Dobrott, C. I., Li, L., Ryba, A. R., et al. (2018). Massively parallel single nucleus transcriptional profiling defines spinal cord neurons and their activity during behavior. *Cell Rep.* 22, 2216–2225. doi:10.1016/j. celrep.2018.02.003

Shi, Y., Abe, C., Holloway, B. B., Shu, S., Kumar, N. N., Weaver, J. L., et al. (2016). Nalcn is a "leak" sodium channel that regulates excitability of brainstem chemosensory neurons and breathing. J. Neurosci. 36, 8174–8187. doi:10.1523/JNEUROSCI.1096-16. 2016

Tian, J., Bavencoffe, A. G., Zhu, M. X., and Walters, E. T. (2023). Readiness of nociceptor cell bodies to generate spontaneous activity results from background activity of diverse ion channels and high input resistance. *Pain.* doi:10.1097/j.pain. 000000000003091

Wu, L., Wu, Y., Liu, J., Jiang, J., Zhou, C., and Zhang, D. (2023). Sodium leak channel in glutamatergic neurons of the lateral parabrachial nucleus modulates inflammatory pain in mice. *Int. J. Mol. Sci.* 24, 11907. doi:10.3390/ijms241511907

Xie, J., Ke, M., Xu, L., Lin, S., Huang, J., Zhang, J., et al. (2020). Structure of the human sodium leak channel NALCN in complex with FAM155A. *Nat. Commun.* 11, 5831. doi:10.1038/s41467-020-19667-z

Xie, L., Gao, S., Alcaire, S. M., Aoyagi, K., Wang, Y., Griffin, J. K., et al. (2013). NLF-1 delivers a sodium leak channel to regulate neuronal excitability and modulate rhythmic locomotion. *Neuron* 77, 1069–1082. doi:10.1016/j.neuron.2013.01.018

Yadav, A., Matson, K. J. E., Li, L., Hua, I., Petrescu, J., Kang, K., et al. (2023). A cellular taxonomy of the adult human spinal cord. *Neuron* 111, 328–344.e7. e327. doi:10.1016/j. neuron.2023.01.007

Yeh, E., Ng, S., Zhang, M., Bouhours, M., Wang, Y., Wang, M., et al. (2008). A putative cation channel, NCA-1, and a novel protein, UNC-80, transmit neuronal activity in *C. elegans. PLoS Biol.* 6, e55. doi:10.1371/journal.pbio.0060055

Yeh, S. Y., Huang, W. H., Wang, W., Ward, C. S., Chao, E. S., Wu, Z., et al. (2017). Respiratory network stability and modulatory response to substance P require nalcn. *Neuron* 94, 294–303. e294. doi:10.1016/j.neuron.2017.03.024

Zhang, D., Wei, Y., Liu, J., Chen, H., Li, J., Zhu, T., et al. (2021). *Single-nucleus transcriptomic atlas of spinal cord neuron in human*. bioRxiv. Available at: https://www.biorxiv.org/content/10.1101/2021.09.28.462103v1.

Zhang, D., Wei, Y., Liu, J., Yang, Y., Ou, M., Chen, Y., et al. (2022). Single-nucleus transcriptomic analysis reveals divergence of glial cells in peripheral somatosensory system between human and mouse. bioRxiv. Available at: https://www.biorxiv.org/content/10. 1101/2022.02.15.480622v1.full.

Zhang, D., Chen, Y., Wei, Y., Chen, H., Wu, Y., Wu, L., et al. (2023). Spatial transcriptomics and single-nucleus RNA sequencing reveal a transcriptomic atlas of adult human spinal cord. *eLife.* doi:10.7554/eLife.92046.1

Zhang, D., Zhao, W., Liu, J., Ou, M., Liang, P., Li, J., et al. (2021). Sodium leak channel contributes to neuronal sensitization in neuropathic pain. *Prog. Neurobiol.* 202, 102041. doi:10.1016/j.pneurobio.2021.102041

Zhou, C., Zhou, Q., He, X., He, Y., Wang, X., Zhu, X., et al. (2022). Differential modulation of *C. elegans* motor behavior by NALCN and two-pore domain potassium channels. *PLoS Genet.* 18, e1010126. doi:10.1371/journal.pgen.1010126

Zhou, H., Li, M., Zhao, R., Sun, L., and Yang, G. (2023). A sleep-active basalocortical pathway crucial for generation and maintenance of chronic pain. *Nat. Neurosci.* 26, 458–469. doi:10.1038/s41593-022-01250-y

Zhou, L., Liu, H., Zhao, Q., Wu, J., and Yan, Z. (2022). Architecture of the human NALCN channelosome. *Cell Discov.* 8, 33. doi:10.1038/s41421-022-00392-4

Zhou, W., Jin, Y., Meng, Q., Zhu, X., Bai, T., Tian, Y., et al. (2019). A neural circuit for comorbid depressive symptoms in chronic pain. *Nat. Neurosci.* 22, 1649–1658. doi:10. 1038/s41593-019-0468-2